Literature DB >> 28439340

The Role of IL-17 in the Pathogenesis and Treatment of Psoriasis.

Joshua A Zeichner1, April Armstrong2.   

Abstract

Entities:  

Year:  2016        PMID： 28439340      PMCID： PMC5395242     

Source DB:  PubMed          Journal:  J Clin Aesthet Dermatol        ISSN： 1941-2789


× No keyword cloud information.
  38 in total

1.  The clinical relevance of maintaining the functional integrity of the stratum corneum in both healthy and disease-affected skin.

Authors:  James Q Del Rosso; Jacqueline Levin
Journal:  J Clin Aesthet Dermatol       Date:  2011-09

Review 2.  Regulation generation: the suppressive functions of human regulatory T cells.

Authors:  Wendy A Goodman; Kevin D Cooper; Thomas S McCormick
Journal:  Crit Rev Immunol       Date:  2012       Impact factor: 2.214

3.  In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin.

Authors:  Gamze Piskin; Regien M R Sylva-Steenland; Jan D Bos; Marcel B M Teunissen
Journal:  J Immunol       Date:  2006-02-01       Impact factor: 5.422

4.  Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis.

Authors:  Andrea Chiricozzi; Emma Guttman-Yassky; Mayte Suárez-Fariñas; Kristine E Nograles; Suyan Tian; Irma Cardinale; Sergio Chimenti; James G Krueger
Journal:  J Invest Dermatol       Date:  2010-11-18       Impact factor: 8.551

Review 5.  The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings.

Authors:  David A Martin; Jennifer E Towne; Gregory Kricorian; Paul Klekotka; Johann E Gudjonsson; James G Krueger; Chris B Russell
Journal:  J Invest Dermatol       Date:  2012-06-07       Impact factor: 8.551

Review 6.  Quality of life in patients with psoriasis: a systematic literature review.

Authors:  John de Korte; Mirjam A Sprangers; Femke M Mombers; Jan D Bos
Journal:  J Investig Dermatol Symp Proc       Date:  2004-03

Review 7.  Immunology of psoriasis.

Authors:  Michelle A Lowes; Mayte Suárez-Fariñas; James G Krueger
Journal:  Annu Rev Immunol       Date:  2014       Impact factor: 28.527

8.  Secukinumab treatment of plaque psoriasis shows early improvement in DLQI response - results of a phase II regimen-finding trial.

Authors:  M Augustin; S Abeysinghe; U Mallya; A Qureshi; N Roskell; D McBride; C Papavassillis; J Gelfand
Journal:  J Eur Acad Dermatol Venereol       Date:  2015-12-10       Impact factor: 6.166

9.  The skin surface as antimicrobial barrier: present concepts and future outlooks.

Authors:  Jürgen Harder; Jens-Michael Schröder; Regine Gläser
Journal:  Exp Dermatol       Date:  2012-10-23       Impact factor: 3.960

10.  Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity.

Authors:  Lam C Tsoi; Sarah L Spain; Jo Knight; Eva Ellinghaus; Philip E Stuart; Francesca Capon; Jun Ding; Yanming Li; Trilokraj Tejasvi; Johann E Gudjonsson; Hyun M Kang; Michael H Allen; Ross McManus; Giuseppe Novelli; Lena Samuelsson; Joost Schalkwijk; Mona Ståhle; A David Burden; Catherine H Smith; Michael J Cork; Xavier Estivill; Anne M Bowcock; Gerald G Krueger; Wolfgang Weger; Jane Worthington; Rachid Tazi-Ahnini; Frank O Nestle; Adrian Hayday; Per Hoffmann; Juliane Winkelmann; Cisca Wijmenga; Cordelia Langford; Sarah Edkins; Robert Andrews; Hannah Blackburn; Amy Strange; Gavin Band; Richard D Pearson; Damjan Vukcevic; Chris C A Spencer; Panos Deloukas; Ulrich Mrowietz; Stefan Schreiber; Stephan Weidinger; Sulev Koks; Külli Kingo; Tonu Esko; Andres Metspalu; Henry W Lim; John J Voorhees; Michael Weichenthal; H Erich Wichmann; Vinod Chandran; Cheryl F Rosen; Proton Rahman; Dafna D Gladman; Christopher E M Griffiths; Andre Reis; Juha Kere; Rajan P Nair; Andre Franke; Jonathan N W N Barker; Goncalo R Abecasis; James T Elder; Richard C Trembath
Journal:  Nat Genet       Date:  2012-11-11       Impact factor: 38.330
View more
  9 in total

1.  Human CD8 T-cell activation in acute and chronic chikungunya infection.

Authors:  Cinthia Nóbrega de Sousa Dias; Bruna Macêdo Gois; Viviane Silva Lima; Isabel Cristina Guerra-Gomes; Josélio Maria Galvão Araújo; Juliana de Assis Silva Gomes; Demétrius Antônio Machado Araújo; Isac Almeida Medeiros; Fátima de Lourdes Assunção Araújo de Azevedo; Robson Cavalcanti Veras; Daniele Idalino Janebro; Ian Porto Gurgel do Amaral; Tatjana Souza Lima Keesen
Journal:  Immunology       Date:  2018-09-03       Impact factor: 7.397

2.  Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study.

Authors:  Antonio Costanzo; Filomena Russo; Marco Galluzzo; Luca Stingeni; Roberta Scuderi; Leonardo Zichichi; Manuela Papini; Luisa Di Costanzo; Andrea Conti; Martina Burlando; Andrea Chiricozzi; Francesca Maria Gaiani; Cristina Mugheddu; Maria Letizia Musumeci; Paolo Gisondi; Stefano Piaserico; Paolo Dapavo; Marina Venturini; Gianluca Pagnanelli; Paolo Amerio; Concetta Potenza; Ketty Peris; Franca Cantoresi; Sara Trevisini; Francesco Loconsole; Annamaria Offidani; Santo Raffaele Mercuri; Viviana Lora; Francesca Prignano; Marta Bartezaghi; Giovanni Oliva; Elisabetta Aloisi; Roberto Orsenigo
Journal:  Acta Derm Venereol       Date:  2021-10-21       Impact factor: 3.875

3.  Secukinumab Improves Patient Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: A Post hoc Analysis of the SUPREME Study.

Authors:  Marina Talamonti; Giovanna Malara; Ylenia Natalini; Federico Bardazzi; Andrea Conti; Andrea Chiricozzi; Cristina Mugheddu; Paolo Gisondi; Stefano Piaserico; Gianluca Pagnanelli; Paolo Amerio; Concetta Potenza; Franca Cantoresi; Maria Concetta Fargnoli; Anna Balato; Francesco Loconsole; Annamaria Offidani; Claudio Bonifati; Francesca Prignano; Marta Bartezaghi; Alice Rausa; Elisabetta Aloisi; Roberto Orsenigo; Antonio Costanzo
Journal:  Acta Derm Venereol       Date:  2021-03-31       Impact factor: 3.875

4.  Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients.

Authors:  S Gerdes; A Pinter; C Papavassilis; M Reinhardt
Journal:  J Eur Acad Dermatol Venereol       Date:  2019-10-10       Impact factor: 6.166

5.  Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial.

Authors:  C Bodemer; A Kaszuba; K Kingo; A Tsianakas; A Morita; E Rivas; P Papanastasiou; D Keefe; M Patekar; P Charef; L Zhang; S Cafoncelli; C Papavassilis
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-01-19       Impact factor: 6.166

6.  Effectiveness and Safety of Secukinumab for Psoriasis in a Real-World Clinical Setting in the Asia-Pacific and Middle East Regions: Results from the REALIA Study.

Authors:  Peter Foley; Tsen-Fang Tsai; Karl Rodins; Issam Ribhi Hamadah; Alfred Ammoury; Hussein Abdel Dayem; Mahmoud Abdallah; Susanne Crowe; Silvia Haas; Effie Pournara; Piotr Jagiello; Yu-Huei Huang
Journal:  Dermatol Ther (Heidelb)       Date:  2022-01-17

7.  The Societal Economic Impact of Secukinumab in First-Line Treatment of Moderate to Severe Plaque Psoriasis in Germany: An Open-Cohort Simulation.

Authors:  Ahmed H Seddik; Nima Melzer; Foteini Tsotra; Dennis A Ostwald
Journal:  Pharmacoecon Open       Date:  2021-10-19

8.  Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results).

Authors:  Jerry Bagel; John Nia; Peter W Hashim; Manmath Patekar; Ana de Vera; Sophie Hugot; Kuan Sheng; Summer Xia; Isabelle Gilloteau; Elisa Muscianisi; Andrew Blauvelt; Mark Lebwohl
Journal:  Dermatol Ther (Heidelb)       Date:  2018-10-17

9.  Safety and effectiveness of secukinumab in psoriasis vulgaris and psoriatic arthritis: Real-world evidence in Japan.

Authors:  Hideki Fujita; Mamitaro Ohtsuki; Akimichi Morita; Ryuji Nagao; Noriko Seko; Kazuko Matsumoto; Yumiko Tani; Tadashi Terui
Journal:  J Dermatol       Date:  2020-10-25       Impact factor: 4.005
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.